drugset / Trial / NCT00788606
R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study evaluates the use of the standard treatment R-CHOP plus the anti-VEGF drug, bevacizumab and whether this treatment is feasible in patients with stage II, III and IV diffuse large B cell lymphoma (DLBCL).
Timeline
- Start
- 2008-05
- Primary completion
- 2010-06
- Completion
- 2010-06
Outcome
Outcome not reported
Stopped: “Toxicity and efficacy data from another trial”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |